by barry-jtcir | Jul 1, 2024 | Press Releases
LA JOLLA, CA, July 01, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...
by barry-jtcir | Jun 28, 2024 | Press Releases
LA JOLLA, CA, June 28, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...
by barry-jtcir | Jun 27, 2024 | Press Releases
Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation LA JOLLA, CA, June 27, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
by barry-jtcir | Jun 27, 2024 | Press Releases
LA JOLLA, CA, June 27, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...
by barry-jtcir | Jun 14, 2024 | Press Releases
GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
by barry-jtcir | May 22, 2024 | Press Releases
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to watch the “What This Means” segment LA JOLLA, CA, May 22, 2024...
